Designing a First-in-Human Dose-Escalation and Dose-Optimization Study of an Oral Covalent KRAS G12C Inhibitor: Translational and Regulatory Strategy and Phase 1 Protocol Synopsis
Early oncology development has moved away from treating the maximum tolerated dose as the default recommended dose, and a covalent inhibitor whose effect depends on how much of a rapidly resynthesized target it occupies is a case in which that shift matters. This article develops the translational and regulatory strategy and a complete protocol synopsis for a hypothetical first-in-human study of a second-generation oral covalent KRAS G12C inhibitor in adults with advanced solid tumors. It derives a 100 mg once-daily starting dose from assumed ICH S9 toxicology benchmarks (rat STD10 and dog HNSTD), verifies the arithmetic, and sets five dose levels from 100 to 800 mg under a Bayesian optimal interval (BOIN) design with a 25% target dose-limiting toxicity rate, after a seven-day single-dose pharmacokinetic run-in. Part B randomizes about 30 patients with lung cancer between two candidate doses to compare exposure-response, target occupancy, and tolerability before a recommended Phase 2 dose is chosen. The synopsis specifies eligibility, schedules, dose-limiting toxicity rules, and stopping rules including exposure ceilings, and states every assumed value as an assumption.Keywords: first-in-human; KRAS G12C; covalent inhibitor; ICH S9; BOIN design; dose optimization; target occupancy; Phase 1 protocol
Authors
- Mounika Battula
- Peivand Pirouzi
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24426679
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00